PCM
CRVS icon

Prelude Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Prelude Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,027
Closed -$31.9K – 1061
2025
Q1 		$31.9K Buy
+10,027
New +$47.2K ﹤0.01% 1113
2018
Q3 		– Sell
-939
Closed -$10K – 1768
2018
Q2 		$10K Buy
+939
New +$10.5K ﹤0.01% 1485
2017
Q2 		– Sell
-14,852
Closed -$308K – 1636
2017
Q1 		$308K Buy
14,852
+5,450
+58% +$85.4K 0.03% 424
2016
Q4 		$134K Buy
+9,402
New +$143K 0.02% 733

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return